Show simple item record

Considerations for Management of Longitudinal Melanonychia During the COVID-19 Pandemic: An International Perspective

dc.contributor.authorLipner, Shari R.
dc.contributor.authorIorizzo, Matilde
dc.contributor.authorJellinek, Nathaniel
dc.contributor.authorPiraccini, Bianca Maria
dc.contributor.authorScher, Richard K.
dc.date2022-08-11T08:08:11.000
dc.date.accessioned2022-08-23T15:45:24Z
dc.date.available2022-08-23T15:45:24Z
dc.date.issued2020-05-13
dc.date.submitted2020-05-18
dc.identifier.citation<p>Lipner SR, Iorizzo M, Jellinek N, Piraccini BM, Scher RK. Considerations for Management of Longitudinal Melanonychia During the COVID-19 Pandemic: An International Perspective. J Am Acad Dermatol. 2020 May 13. doi: 10.1016/j.jaad.2020.05.028. Epub ahead of print. PMID: 32405124; PMCID: PMC7217794. <a href="https://doi.org/10.1016/j.jaad.2020.05.028">Link to article on publisher's site</a></p>
dc.identifier.issn0190-9622 (Linking)
dc.identifier.doi10.1016/j.jaad.2020.05.028
dc.identifier.pmid32405124
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27519
dc.description.abstractTo the editor: 34 Longitudinal melanonychia (LM) is the presenting sign of nail unit melanoma (NUM) in 2/3 35 of cases and is therefore among the most important conditions managed by dermatologists. In 36 normal times, referral for LM would prompt an expedited appointment for clinical 37 examination and dermoscopy.1 However, due to SARS-CoV-2, dermatologists have been 38 asked to reconsider “urgent/emergency” conditions. The COVID-19 pandemic has propelled 39 physicians to unexpectedly adopt telemedicine without adequate guidance for managing LM 40 patients.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32405124&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217794/
dc.rights© 2020 by the American Academy of Dermatology. This is a PDF file of an accepted manuscript that has been accepted for publication and posted with a 12-month embargo and CC BY-NC-ND license as allowed by the publisher's author rights policy at https://www.elsevier.com/about/policies/sharing.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectcoronavirus
dc.subjectdermoscopy
dc.subjecten bloc excision
dc.subjecthemostasis
dc.subjectlongitudinal melanonychia
dc.subjectmelanocytic activation
dc.subjectnail biopsy
dc.subjectnail matrix nevus
dc.subjectnail unit melanoma
dc.subjectonychoscopy
dc.subjectpandemic
dc.subjectsubungual melanoma
dc.subjecttelemedicine
dc.subjectDermatology
dc.subjectHealth Services Administration
dc.subjectInfectious Disease
dc.subjectSkin and Connective Tissue Diseases
dc.subjectTelemedicine
dc.subjectVirus Diseases
dc.titleConsiderations for Management of Longitudinal Melanonychia During the COVID-19 Pandemic: An International Perspective
dc.typeAccepted Manuscript
dc.source.journaltitleJournal of the American Academy of Dermatology
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1034&amp;context=covid19&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/32
dc.legacy.embargo2021-05-13T00:00:00-07:00
dc.identifier.contextkey17785901
refterms.dateFOA2022-08-23T15:45:24Z
html.description.abstract<p>To the editor: 34 Longitudinal melanonychia (LM) is the presenting sign of nail unit melanoma (NUM) in 2/3 35 of cases and is therefore among the most important conditions managed by dermatologists. In 36 normal times, referral for LM would prompt an expedited appointment for clinical 37 examination and dermoscopy.1 However, due to SARS-CoV-2, dermatologists have been 38 asked to reconsider “urgent/emergency” conditions. The COVID-19 pandemic has propelled 39 physicians to unexpectedly adopt telemedicine without adequate guidance for managing LM 40 patients.</p>
dc.identifier.submissionpathcovid19/32
dc.contributor.departmentDepartment of Dermatology


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1_s2.0_S0190962220308598_main.pdf
Size:
792.0Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

© 2020 by the American Academy of Dermatology. This is a PDF file of an accepted manuscript that has been accepted for publication and posted with a 12-month embargo and CC BY-NC-ND license as allowed by the publisher's author rights policy at https://www.elsevier.com/about/policies/sharing.
Except where otherwise noted, this item's license is described as © 2020 by the American Academy of Dermatology. This is a PDF file of an accepted manuscript that has been accepted for publication and posted with a 12-month embargo and CC BY-NC-ND license as allowed by the publisher's author rights policy at https://www.elsevier.com/about/policies/sharing.